Embattled Midatech Receives Lifeline From China To Save Cancer Candidate
Executive Summary
A Chinese billionaire has invested in UK biotech Midatech and signed a licensing deal for an as yet unapproved carcinoid cancer drug, sending it much-needed backing just days after the company said it did not have enough cash to get it to the second half of the year.